Sempre Health rakes in $8 million to improve patient behavior and medication adherence
Rethink Impact led the Series A round, which will be used to grow Sempre's relationships with health plans and to make its service available to more patients.
Rethink Impact led the Series A round, which will be used to grow Sempre's relationships with health plans and to make its service available to more patients.
The medication adherence collaboration with Novo Nordisk and Sempre Health will focus on incentivizing diabetes patients.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Sempre Health Cofounder and CEO Anurati Mathur said the first pilot will focus on heart patients.